GO
Loading...

Japan's Takeda to Buy Millennium Pharma

Takeda Pharmaceutical said it would buy U.S. firm Millennium Pharmaceuticals for $8.8 billion to boost its cancer drug business, in the biggest overseas acquisition by a Japanese drug maker.

The friendly cash offer of $25 per share -- 53 percent above Millennium's

closing share price on Wednesday -- is the latest example of accelerating M&A in the biotech sector as drugmakers scramble to secure promising technologies and pipelines developed by smaller firms.

Takeda, Japan's largest drugmaker, has long been under pressure to use a $10 billion war chest to strengthen its pipeline before a U.S. patent on its top-selling diabetes drug, Actos, expires in 2011.

Developing cancer drug pipelines has been a top priority for Japanese drug makers which have been late to step into the lucrative business.

The deal comes on the heels of rival Eisai's $3.9 billion purchase of cancer specialist MGI Pharma.

It also follows Takeda's agreement with Abbott Laboratories last month to split their 50-50 joint venture TAP Pharmaceutical Products.

The Millennium purchase adds blood cancer drug Velcade to Takeda's portfolio. The U.S. biotech firm forecast in January that Velcade would produce $320-$345 million in sales this year, up around a quarter from 2007.

Millennium, which had $528 million in revenues last year, also has a potential therapy for inflammatory bowel disease, which is expected to enter late stage clinical trials in late 2008 or early 2009.

The deal was conditional on majority acceptance of the offer by Millennium shareholders, the companies said in a joint statement.

UBS Investment Bank was advising Takeda, while Goldman Sachs was advising Millennium.

Takeda also said on Thursday it would buy back up to 60 billion yen ($593 million) of its own shares.

Takeda shares fell 2.5 percent on Thursday to close at 5,410 yen before the bid was announced, underperforming a 1.3 percent fall in the Nikkei share index.

Contact M&A

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    To learn more about how we use your information,
    please read our Privacy Policy.
    › Learn More